Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioInvent International AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $-51.18 Mil. BioInvent International AB's average total tangible assets for the quarter that ended in Mar. 2026 was $64.82 Mil. Therefore, BioInvent International AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -78.96%.
The historical rank and industry rank for BioInvent International AB's Return-on-Tangible-Asset or its related term are showing as below:
BOVNF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -84.81 Med: -36.9 Max: -2.69
Current: -44.39
During the past 13 years, BioInvent International AB's highest Return-on-Tangible-Asset was -2.69%. The lowest was -84.81%. And the median was -36.90%.
BOVNF's Return-on-Tangible-Asset is ranked worse than 56.43% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs BOVNF: -44.39
BioInvent International AB (OTCPK:BOVNF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BioInvent International AB Return-on-Tangible-Asset Related Terms
BioInvent International AB Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB Return-on-Tangible-Asset Chart
BOVNF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, BioInvent International AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -78.96% mean?
BioInvent International AB (BOVNF) has a Return-on-Tangible-Asset of -78.96% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #799 out of 1416 companies in the Biotechnology industry, placing it in the top 56.4%.
Is BioInvent International AB's Return-on-Tangible-Asset too high?
BioInvent International AB's current Return-on-Tangible-Asset is -78.96%. Based on the distribution chart, BioInvent International AB ranks #799 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #799 out of 1416 companies for Return-on-Tangible-Asset. This places BioInvent International AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Return-on-Tangible-Asset is -78.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Return-on-Tangible-Asset of -78.96%. The stock's GF Value™ is $7.07, compared to a current price of $3.29 — trading 53.5% below its estimated fair value. The current Return-on-Tangible-Asset is -78.96%. BioInvent International AB's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Return-on-Tangible-Asset is -78.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 53.5% below its estimated GF Value™ of $7.07.
Key valuation signals for BOVNF:
Return-on-Tangible-Asset: -78.96%
GF Value™: $7.07 vs. price of $3.29 (53.5% below fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
39GF Score
Get the complete analysis for BOVNF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
